Jason Arnold, managing director on William Blair’s healthcare investment banking team, was quoted in biopharma publication Endpoints News in its coverage of the outsized market forecast for GLP-1s, commonly known as obesity-fighting drugs.
“Certainly, you can point to valuations of things and say, ‘Wow, that looks pretty high.’ But there’s a lot of opportunity and growth here, so there’s room for a number of players,” Arnold told the publication.